Bryan Garnier - BIONTECH (BNTX.O) BIONTECH - BUY vs. NEUTRAL | USD451 VS. USD206 (+8%) Positive outlook going forward as COVID news keep driving the share price

Report

Bryan Garnier

Olga Smolentseva

BIONTECH - BUY vs. NEUTRAL | USD451 VS. USD206 (+8%) Positive outlook going forward as COVID news keep driving the share price

BIONTECH - BUY vs. NEUTRAL | USD451 VS. USD206 (+8%)
Positive outlook going forward as COVID news keep driving the share price

Financial update
COVID vaccine remains the main value driver over the short-mid term
Oncology franchise could provide significant boost over mid- to long-term
TP increase to USD451, upgrade to BUY

11/08/2021 5 EN

Underlying

BIONTECH

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Olga Smolentseva

Other Reports on these Companies

Bryan Garnier

BIONTECH - BUY | USD308 While minimally disclosed, clinical data support preclinical evidence for BA.4/5 booster

October 14, 2022 October 14, 2022 1 EN

Bryan Garnier

BIONTECH: ESMO late-breaking presentation to substantiate the CAR-T case | BUY | USD308

BIONTECH - BUY | USD308 ESMO late-breaking presentation to substantiate the CAR-T case

September 8, 2022 September 8, 2022 1 EN

Bryan Garnier

BIONTECH - BUY | USD308 Omicron-adapted booster sets a precedent for EUA approval based on preclinical data

FDA approves bivalent booster setting the precedent of preclinical data use Another lawsuit targeting mRNA technology, but we do not expect a significant impact on net revenues

September 1, 2022 September 1, 2022 1 EN

Median Technologies: reports Q1 2024 results

Median reconfirmed previously shared FY 2023 and reported Q1 2024 results this morning. FY 2023 sales were confirmed at EUR 22.2m representing a 7% drop vs. 2022, as iCRO business has been hampered by the COVID crisis in China. While the first three-quarter 2023 revenues were stable at ~5.6m per qu

17h / 58m 17h / 58m 1 EN

Clement Genelot

Clement Genelot

Jeronimo Martins: Q1 topping expectations; price war ongoing in Poland

With Q1 topping expectations in terms of both sales and EBITDA, notably thanks to Biedronla, we foresee a positive share price reaction this morning. But reiterated gloomy FY guidance combined with no early signs of the price war easing in Poland still suggests caution is advisable.

19h / 34m 19h / 34m 1 EN

Paul de Froment ... (+3)

Paul de Froment
Sebastián Marroquin Mérida
Thomas Mordelle

Nel: Capacity reservation agreement with Hy Stor Energy

This morning, Nel announced a multi-year capacity reservation agreement (CRA) with Hy Stor Energy, representing more than 1GW of alkaline electrolyser capacity combined over 2025/2027, for its Mississippi Clean Hydrogen Hub (MCHH) project. The project is still pending regulatory approvals, financin

19h / 46m 19h / 46m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BIONTECH - BUY vs. NEUTRAL | USD451 VS. USD206 (+8%) Positive outlook going forward as COVID news keep driving the share price

BIONTECH - BUY | USD308 While minimally disclosed, clinical data support preclinical evidence for BA.4/5 booster

BIONTECH: ESMO late-breaking presentation to substantiate the CAR-T case | BUY | USD308

BIONTECH - BUY | USD308 Omicron-adapted booster sets a precedent for EUA approval based on preclinical data

Median Technologies: reports Q1 2024 results

Jeronimo Martins: Q1 topping expectations; price war ongoing in Poland

Nel: Capacity reservation agreement with Hy Stor Energy

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe